It would be fair to say that there's still a lot that we need to learn and understand about these agents and how they work, what patients are suitable and what conditions are amenable to these sorts of treatments, he said.
In commentary published in the Australian and New Zealand Journal of Psychiatry, some neuropsychologists and neuroscientists said they feared the decision was driven by the influence of lobby groups instead of health experts and evidence.
#psychedelic-therapy #psychiatry #mdma #psilocybin #medical-use-of-psychedelics #therapeutic-goods-administration
[
add
]
[
|
|
...
]